Scientific Presentations for Products in Development

Clovis Oncology presents data on its products in development at a variety of medical conferences. Our current and historic presentations are provided in the following links.

Characterization of Patients With Long-term Responses to Rucaparib in Recurrent Ovarian Cancer

Virtual Presentation 2020 ASCO

documentImage.GetPropertyValue(

Postprogression Outcomes in Patients With Ovarian Carcinoma Associated With a Mutation in a Non-<i>BRCA</i>Homologous Recombination Repair Gene Receiving Rucaparib Maintenance Treatment: Results From the Phase 3 Study ARIEL3

Webinar Presentation 2020 SGO

documentImage.GetPropertyValue(

Population Exposure-Safety and Exposure-Efficacy Analyses for Rucaparib in Patients With Recurrent Ovarian Carcinoma From Study 10 and ARIEL2

Poster Presentation 2020 SGO

documentImage.GetPropertyValue(

Rucaparib for recurrent, locally advanced or metastatic urothelial carcinoma: results from ATLAS, a phase 2, open-label trial

Presented at 2020 ASCO GU

documentImage.GetPropertyValue(

Genomic characteristics associated with clinical activity of rucaparib in patients (pts) with <i>BRCA1</i> or <i>BRCA2</i> (<i>BRCA</i>)-mutated metastatic castration-resistant prostate cancer (mCRPC)

Presented at 2020 ASCO GU

documentImage.GetPropertyValue(

Combination of the Angiogenesis Inhibitor Lucitanib with Immune Checkpoint Blockade Augments Anti-tumor Activity in Syngeneic Models

Presented at 2019 SITC

documentImage.GetPropertyValue(

ATHENA (GOG-3020/ENGOT-ov45): A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Poly(ADP-Ribose) Polymerase (PARP) Inhibitor Rucaparib + the PD-1 Inhibitor Nivolumab Following Frontline Platinum-Based Chemotherapy in Ovarian Cancer

Presented at 2019 ASGO

documentImage.GetPropertyValue(

Integrated safety analysis of the poly(ADP-ribose) polymerase inhibitor rucaparib in patients with ovarian cancer in the treatment and maintenance settings

Presented at 2019 ESMO

documentImage.GetPropertyValue(

Effect of response to last platinum-based chemotherapy in patients (pts) with platinum-sensitive, recurrent ovarian carcinoma in the phase 3 study ARIEL3 of rucaparib maintenance treatment

Presented at 2019 ESMO

documentImage.GetPropertyValue(

Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): updated analyses

Presented at 2019 ESMO

documentImage.GetPropertyValue(

ARIES: A Phase 2, Open-Label Study to Evaluate Rucaparib (PARP Inhibitor) in Combination with Nivolumab (Anti-PD-1 Antibody) in Patients with Ovarian Cancer

Presented at 2019 IGCS

documentImage.GetPropertyValue(